CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	KRAS	Exon 2 Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Irinotecan,Selumetinib	Hochster et al., 2015
E	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Colorectal Adenocarcinoma	Crizotinib	Lin et al., 2009
E	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Breast Cancer	Crizotinib	Lin et al., 2009
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Head And Neck Cancer	Dactolisib	Wirtz et al., 2015
D	CDK4	R24C	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Palbociclib	Young et al., 2014
C	ERBB2	Amplification	Predictive	Supports	Resistance	Lung Adenocarcinoma	Gefitinib,Erlotinib	Yu et al., 2013
C	EGFR	T790M AND EGFR Exon 19 Deletion AND EGFR C797S	Predictive	Supports	Resistance	Lung Adenocarcinoma	Osimertinib	Yu et al., 2015
C	EGFR	T790M AND EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Osimertinib	Yu et al., 2015
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Head And Neck Cancer	Alpelisib	Keam et al., 2015
D	PIK3CA	Amplification	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Taselisib	Zumsteg et al., 2016
D	NRAS	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Amuvatinib	Fedorenko et al., 2014
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Stomach Cancer	Docetaxel,Capivasertib	Li et al., 2013
C	PIK3CA	E545K	Predictive	Supports	Sensitivity/Response	Cancer	Apitolisib	Dolly et al., 2016
B	BRAF	D594G	Prognostic	Supports	Poor Outcome	Colorectal Cancer		Amaki-Takao et al., 2016
C	BRAF	D594G	Predictive	Does Not Support	Resistance	Colorectal Cancer	Cetuximab,Panitumumab	Amaki-Takao et al., 2016
C	FLT3	ITD	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Sorafenib	Baker et al., 2013
D	FLT3	D835H/Y	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Sorafenib	Baker et al., 2013
D	CCND1	Overexpression	Predictive	Supports	Sensitivity/Response	Mantle Cell Lymphoma	Palbociclib	Marzec et al., 2006
C	KIAA1549::BRAF	Fusion	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib	Menzies et al., 2015
D	MET	Overexpression	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	Crizotinib	Surriga et al., 2013
D	STK11	Loss	Predictive	Supports	Sensitivity/Response	Peutz-Jeghers Syndrome	Sirolimus	Wei et al., 2008
D	STK11	Loss	Predictive	Supports	Sensitivity/Response	Peutz-Jeghers Syndrome	Sirolimus	Shackelford et al., 2009
C	AKT2	Amplification	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Vandetanib,Everolimus	Subbiah et al., 2015
C	PTEN	Expression	Predictive	Supports	Resistance	Her2-receptor Positive Breast Cancer	Fulvestrant,Everolimus	Sun et al., 2016
D	MYD88	L265P	Predictive	Supports	Sensitivity/Response	Lymphoplasmacytic Lymphoma	IMG-2005-5,IRAK-1/4 Inhibitor	Treon et al., 2012
D	PIK3CA	Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Bertotti et al., 2011
D	MYCL	EXPRESSION	Predictive	Supports	Sensitivity/Response	Multiple Myeloma	I-BET151,JQ1	Suzuki et al., 2016
B	EGFR	Expression	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Saltz et al., 2004
C	BRCA2	TRUNCATING MUTATION	Predisposing	Supports	Predisposition	Breast Cancer		Teugels et al., 2005
C	EGFR	E746G	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Klughammer et al., 2016
C	MLH1	E13fs	Oncogenic	Supports	Oncogenicity	Endometrial Cancer		Geurts-Giele et al., 2014
C	MSH2	R383*	Oncogenic	Supports	Oncogenicity	Endometrial Cancer		Geurts-Giele et al., 2014
C	MLH1	V534R	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	G606FS*2	Oncogenic	Supports	Oncogenicity	Endometrial Cancer		Geurts-Giele et al., 2014
C	MLH1	c.790+1G>A	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	K618DEL	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	R687FS	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	R100*	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	T117M	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	Q426FS	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	V49A	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	D667FS	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	M1L	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	*757L	Oncogenic	Supports	Oncogenicity	Villous Adenoma		Geurts-Giele et al., 2014
C	MLH1	R265G	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	V213FS	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	N551T	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	A424T	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	Q149*	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014
C	MLH1	R226*	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		Geurts-Giele et al., 2014

Page 90 of 96

Previous Next